Auriga maintains a 'Buy' on Exact Sciences (EXAS); Timelines on Track; Tweaks Sample Container and Marker Panel

August 3, 2011 7:23 AM EDT
Get Alerts EXAS Hot Sheet
Price: $104.91 --0%

Rating Summary:
    8 Buy, 27 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga maintains a 'Buy' on Exact Sciences (NASDAQ: EXAS) price target of $10.00.

Auriga analyst says, "EXAS reported 2Q11 results of $1.0MM/$(0.13), which were essentially in line with our estimates and consensus. Given EXAS's stage of development, earnings are not as important as development milestones. We note EXAS continues to improve test attributes, and we expect additional data from its 300 patient validation study could be presented later this year. Overall , EXAS continues to make steady progress on what could potentially be a game-changer in colorectal cancer screening."

"We estimate in 2015 (our valuation year) EXAS' test will penetrate 4% of the 27MM person screening population - translating to 969,000 tests and $242MM in sales."

For more ratings news on Exact Sciences click here and for the rating history of Exact Sciences click here.

Shares of Exact Sciences closed at $7.76 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Auriga, Earnings